Consort Partners’ Post

Insilico’s New Paper Describing the Discovery & Validation of Novel TNIK Inhibitors I am pleased to share that last Friday, the 8th of March 2024, Insilico Medicine announced a major publication in #NatureBiotechnolgy offering an in-depth look at the journey of its lead compound "INS018_055". This story began with the discovery and validation of the AI-discovered multi-purpose target, TNIK, to the nomination of Insilico Medicine’s novel molecule using generative AI for the treatment of patients with IPF, with the company performing further indication expansion and additional in vitro validation through its fully robotic 6th generation laboratory platform, LifeStar1. This not only marked the first time TNIK was identified as a target specifically for Idiopathic Pulmonary Fibrosis (IPF) but also set a record timeline from target discovery to human clinical trials with the whole process taking around 18 months, supporting the validation of the proof of concept around applied generative AI in innovative medicines development. The program is currently in Phase II clinical trials with data expected to readout later this year. This paper provides a detailed look at Insilico Medicine’s AI software platforms, 300 GB of live data including many preclinical experiments leading to PCC, the results of the Phase I study in humans and a custom GPT for asking interactive questions. Generative AI is well positioned to transform the Life Sciences Industry and Insilico Medicine is leading the way with its end-to-end next generation AI Drug Discovery Platforms PandaOmics, Chemistry42 & inClinico and exciting Pipeline of molecules in development - https://lnkd.in/dNVnZZpv, which we are currently looking for partners. The Insilico team will be attending multiple conferences globally and we're looking forward to connect, collaborate and make history happen together! Feel free to reach out at ricardo@insilicomedicine.com Link to the article: https://lnkd.in/d2M5XaHb (DOI: 10.1038/s41587-024-02143-0) #NaturePortfolio #ai #genai #generativeai #techbio #biotech #pharma #drugdiscovery #innovativemedicines #partnering #businessdevelopment #agingresearch

Why do I have to convince mainstream audiences about the potential of AI in drug discovery? Every groundbreaking advancement in healthcare faces the challenge of transitioning from cutting-edge research to practical application. Owkin, a pioneer in TechBio, is overcoming this challenge with its revolutionary AI-driven approach to precision drug discovery and development. Unlike traditional methods, their precision pipeline harnesses the power of causal AI, unlocking insights from vast amounts of patient data to tailor treatments to specific patient subgroups. Their recent unveiling of a pipeline featuring OKN4395, a best-in-class dual inhibitor of prostanoid receptors EP2 and EP4, marks a significant leap forward in oncology and immunology. Their journey from data to clinical trials showcases the power of AI in transforming drug discovery. Through meticulous processes, their AI engines select the most promising assets for in-licensing, backed by rich multimodal patient data and validated by medical experts. The decision to bring OKN4395 into clinical development underscores Owkin's commitment to delivering clinical benefits to patients sooner. By combining expertise in biomarker discovery, drug positioning, and clinical trial optimization, Owkin is paving the way for personalized medicine on a scale never seen before. We are also on a journey to redefine the boundaries of possibility in healthcare, From developing our IoT-based asset tracking system, iTrack, to creating midoc - the world’s first AI-powered, patient-centric healthcare app, The future of precision medicine looks brighter than ever.

Thank you, Idrees Mohammed, for sharing these insights on AI's potential in drug discovery. Owkin's approach is indeed a testament to how AI can revolutionize precision medicine by leveraging causal AI to unlock deeper insights from patient data and tailor treatments effectively. Convincing mainstream audiences about the potential of AI in drug discovery is crucial because widespread understanding and acceptance drive adoption and support. It ensures that stakeholders, including patients, healthcare providers, and regulatory bodies, are aligned and confident in the technology's capabilities and benefits. Highlighting success stories like OKN4395's progression from data to clinical trials can demonstrate AI's tangible impact and build trust. Additionally, emphasizing AI's role in accelerating drug discovery, optimizing clinical trials, and ultimately delivering personalized treatments can further solidify its value proposition. How can we best communicate these advancements to foster a deeper understanding and acceptance of AI in drug discovery among mainstream audiences? #PrecisionMedicine #AIDrugDiscovery #HealthTech #eHealth #DigitalHealth

Alex Zhavoronkov and his team at Insilico Medicine are truly reshaping the drug development journey, so learn how your organization can benefit from the latest #generativeai , focused on #lifescience.

In the realm of healthcare innovation, the integration of AI with mRNA therapeutics represents a transformative leap forward. Essential to this advancement is the requirement that AI development data accurately represent the diverse populations it serves. This data integrity is pivotal, particularly in research, clinical development, and pharmacovigilance, paving the way for precise, tailored treatments that enhance patient outcomes. Together, AI and mRNA herald a future where healthcare meets individual needs with unprecedented accuracy and efficacy. An insightful article by Manasi Vaidya on the impact of data on advancements in AI and mRNA therapeutics. #AIinHealthcare #PrecisionMedicine #TargetedTherapies #PatientOutcomes #HealthcareInnovation

Feng Ren et al. illustrate the potential of #GenerativeAI for #DrugDiscovery: from target discovery to preclinical candidate nomination in only 18 months. Curious what the phase II and phase III clinical trials will look like.

The FDA released its draft guidance in support of Project Optimus in January 2023. It offers clear direction for industry stakeholders to unlock efficiencies in oncology drug and biologic development. The FDA’s draft guidance also underscores the benefits patient-centric approaches can have on quality of life, medication adherence, and long-term clinical outcomes. “The baton has now been passed to the life sciences industry to harness its resources to drive efficiencies in process and enable a patient-first mindset. AI arguably is the most essential tool at our disposal for unlocking those efficiencies and reaping the benefits of breakthrough science. It's up to us as stewards to ensure that the right drugs now reach the right patients at the right dose.” Our CEO and co-founder, Sirj Goswami, PhD, and our VP of Global Biopharma, Jason Rizzo, MBA, dive in to discuss how with its draft guidance, the FDA has placed adaptive trials and, more specifically, model-informed adaptive trial designs at the forefront of the minds of every oncology drug developer. Read it now via Applied Clinical Trials Magazine: https://bit.ly/3Vdw8nh | #ProjectOptimus #ClinicalTrials #OncologyTreatments #ModelInformedPrecisionDosing #ArtificialIntelligence #LifeSciences

"Clinical trial failures are complex problems that AI is uniquely positioned to solve,” says Alex Aliper, PhD, president of Insilico Medicine. “With this tool, we can help companies determine which programs to prioritize and give investors critical insights into the drug discovery programs that are most likely to succeed.” ➡ More on the recent paper in the leading journal from the American Society for Clinical Pharmacology & Therapeutics highlighting Insilico's generative AI clinical trial prediction tool inClinico from Al Arabiya News Channel. ➡https://lnkd.in/dmhPqtBr #ai #genai #clinicaltrials #prediction #drugdiscovery

Fascinating read - Insilico Medicine's AI-driven drug discovery journey for a Idiopathic pulmonary fibrosis (IPF) candidate. It took just 18 months from target discovery to a preclinical candidate that passed a Phase 1 clinical trial -- a process that typically takes 5-8 years. Reading the article, you can see that Insilico is creating a repeatable process that can apply to conditions agnostically through a set of AI tools for pathway identification, generative chemistry, protein structure, binding affinity and success forecasting for clinical trials. The AI algorithms are paired with basic science, and productivity gains through lab automation and robotics. Other early forrays aren't proving as successful: https://lnkd.in/ebVD8PpB, but time will tell if the array of companies racing forward on AI in drug discovery, and the capability building at Pharma companies drive real productivity gains in Pharma R&D.

The future of Pharma is set to be full of innovation and groundbreaking advanced therapies but what are the key trends likely to redefine the sector's outlook in 2024? Personal medicines, data driven innovations, collaboration and digital revolution are just a few of the most pertinent trends that are set to dominate the landscape over 2024. You can read more about some of the predictions that look set to dominate the pharma industry this year in the article below.👇 https://bit.ly/4aH7nF8 #Pharma #AI #Data #Genomics #Domorescience